Long-acting injectable depot naltrexone use in the Veterans' Health Administration: A national study

被引:5
作者
Marienfeld, Carla [1 ]
Iheanacho, Theddeus [1 ]
Issa, Mohammed [1 ]
Kosenheck, Robert A. [2 ]
机构
[1] Yale Univ, Sch Med, West Haven, CT 06516 USA
[2] VA Connecticut Hlth Care Syst, VA New England Mental Illness, Res Educ & Clin Ctr, West Haven, CT 06516 USA
关键词
Naltrexone; Health services research; Depot; Alcohol use disorders treatment; Dual-diagnosis; ALCOHOL DEPENDENCE; DOUBLE-BLIND; EFFICACY; ACAMPROSATE; RELAPSE; MULTICENTER; DISORDERS; COST;
D O I
10.1016/j.addbeh.2013.05.006
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: Alcohol use disorders affect millions, but few utilize medications. This paper examines factors contributing to the use of long-acting injectable depot naltrexone (LADN) in a large patient population. Methods: Bivariate analysis, stepwise multivariate logistic regression, and multivariate logistic regression analysis were used. Results: The sample had 101,026 patients of whom 3180(3.1%) received any form of naltrexone and 240(0.24%) received LADN. Of those who received naltrexone, only 7.5% (240/3180) received LADN. The LADN group was more likely to have outpatient mental health service use and a mental health inpatient admission. The LADN group was more likely to have a co-morbid Axis I psychiatric disorder and to fill a psychotropic prescription. Conclusion: In order to better serve and understand the implications of LADN treatment for the patient population that uses and may benefit from it, more research is needed on the effectiveness of this medication in the dually-diagnosed and high service use population. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:434 / 438
页数:5
相关论文
共 27 条
[1]   Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study [J].
Addolorato, G ;
Caputo, F ;
Capristo, E ;
Domenicali, M ;
Bernardi, M ;
Janiri, L ;
Agabio, R ;
Colombo, G ;
Gessa, GL ;
Gasbarrini, G .
ALCOHOL AND ALCOHOLISM, 2002, 37 (05) :504-508
[2]   Does disulfiram help to prevent relapse in alcohol abuse? [J].
Brewer, C ;
Meyers, RJ ;
Johnsen, J .
CNS DRUGS, 2000, 14 (05) :329-341
[3]   Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence:: a systematic review [J].
Carmen, B ;
Angeles, M ;
Ana, M ;
María, AJ .
ADDICTION, 2004, 99 (07) :811-828
[4]  
Colom Francesc, 2000, Journal of Clinical Psychiatry, V61, P549
[5]   Pharmacological treatment of alcohol dependence - A review of the evidence [J].
Garbutt, JC ;
West, SL ;
Carey, TS ;
Lohr, KN ;
Crews, FT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (14) :1318-1325
[6]   Efficacy and tolerability of long-acting injectable for alcohol dependence - A randomized controlled trial [J].
Garbutt, JC ;
Kranzler, HR ;
O'Malley, SS ;
Gastfriend, DR ;
Pettinati, HM ;
Silverman, BL ;
Loewy, JW ;
Ehrich, EW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (13) :1617-1625
[7]   Pharmacotherapy of Alcohol Use Disorders in the Veterans Health Administration [J].
Harris, Alex H. S. ;
Kivlahan, Daniel R. ;
Bowe, Thomas ;
Humphreys, Keith N. .
PSYCHIATRIC SERVICES, 2010, 61 (04) :392-398
[8]   Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism -: A double-blind, placebo-controlled study [J].
Kiefer, F ;
Jahn, H ;
Tarnaske, T ;
Helwig, H ;
Briken, P ;
Holzbach, R ;
Kämpf, P ;
Stracke, R ;
Baehr, M ;
Naber, D ;
Wiedemann, K .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (01) :92-99
[9]   Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial [J].
Kranzler, HR ;
Wesson, DR ;
Billot, L .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2004, 28 (07) :1051-1059
[10]   Naltrexone in the treatment of alcohol dependence. [J].
Krystal, JH ;
Cramer, JA ;
Krol, WF ;
Kirk, GF ;
Rosenheck, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (24) :1734-1739